CRDF
Cardiff Oncology Inc
1.10$
-5.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 75.9% | 66.0% | 49.8% | 64.4% | 5,842.4% | 63.6% | – | 9,570.2% | – | 91.8% | 539.0% | – | – | |
| 24.1% | 34.0% | 50.2% | 35.6% | -5,742.4% | 100.0% | 100.0% | -9,470.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 5,689.4% | 4,976.3% | 3,906.3% | 5,823.9% | 5,842.4% | 6,431.8% | 9,611.9% | 9,570.2% | 6,830.8% | 2,088.5% | 16,500.0% | 5,687.5% | 5,108.7% | |
| 1,704.3% | 2,844.9% | 1,526.8% | 1,690.8% | 1,894.5% | 1,994.0% | 3,682.6% | 2,742.1% | 3,247.5% | 1,232.5% | 14,941.5% | 3,657.7% | 3,311.4% | |
| 7,697.9% | 6,657.1% | 5,383.4% | 7,731.9% | 1,894.5% | 8,425.8% | 13,294.5% | 2,742.1% | 10,078.3% | 3,321.0% | 31,441.5% | 9,345.2% | 8,420.1% | |
| -7,673.8% | -6,623.1% | -5,333.2% | -7,696.3% | -7,637.0% | -8,325.8% | -13,194.5% | -12,212.4% | -9,978.3% | -3,221.0% | -31,341.5% | -9,245.2% | -8,320.1% | |
| – | 531.4% | – | – | – | – | – | – | – | – | – | – | – | |
| -6,901.4% | -5,985.3% | -4,883.4% | -7,225.8% | -7,184.8% | -7,806.0% | -12,324.8% | -11,523.1% | -9,381.7% | -2,969.5% | -30,109.8% | -8,876.9% | -7,884.1% | |
| -757.4% | 1,891.0% | 28.6% | – | – | – | – | – | – | – | – | – | – | |
| -6,901.4% | -5,985.3% | -4,883.4% | -7,225.8% | -7,184.8% | -7,806.0% | -12,324.8% | -11,523.1% | -9,381.7% | -2,969.5% | -30,109.8% | -8,876.9% | -7,884.1% | |
| -6,825.5% | -5,919.2% | -4,833.7% | -7,161.3% | -7,123.6% | -7,742.4% | -12,115.6% | -11,445.5% | -8,970.0% | -2,877.8% | -29,570.7% | -8,709.6% | -7,665.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.